Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the... editorial memo (2021) 14:221–223 https://doi.org/10.1007/s12254-021-00741-1 SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients? Niklas Zojer Accepted: 19 July 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 Patients with cancer were reported to have an elevated pose cancer patients to severe COVID-19, due to ther- risk of acquiring SARS-CoV-2 (severe acquired respi- apeutically activated T-cells augmenting the virally in- ratory syndrome coronavirus 2) infection [1], possi- duced cytokine storm, but so far these concerns could bly indicating an increased susceptibility to the virus, not be substantiated. As in the general population, and have a high risk of developing severe COVID- mortality of COVID-19 in cancer patients increases 19 (coronavirus disease 2019), as well as dying from substantially with age. Currently, there are insuffi- the disease. In a large study from the US [2], hos- cient data for estimating COVID-19 risks for cancer pitalization for COVID-19 was necessary in 47.46% survivors, i.e., patients in long-term follow-up with- of oncologic patients, who had acquired the disease, out active disease or treatment, but highest risk for and an overall mortality of 14.93% was seen, while severe COVID-19 seems to affect cancer http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?

memo - Magazine of European Medical Oncology , Volume 14 (3): 3 – Sep 1, 2021

Loading next page...
 
/lp/springer-journals/sars-cov-2-vaccination-in-patients-with-solid-tumors-or-hematological-OBYf2X1bLQ

References (29)

Publisher
Springer Journals
Copyright
2021 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00741-1
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2021) 14:221–223 https://doi.org/10.1007/s12254-021-00741-1 SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients? Niklas Zojer Accepted: 19 July 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 Patients with cancer were reported to have an elevated pose cancer patients to severe COVID-19, due to ther- risk of acquiring SARS-CoV-2 (severe acquired respi- apeutically activated T-cells augmenting the virally in- ratory syndrome coronavirus 2) infection [1], possi- duced cytokine storm, but so far these concerns could bly indicating an increased susceptibility to the virus, not be substantiated. As in the general population, and have a high risk of developing severe COVID- mortality of COVID-19 in cancer patients increases 19 (coronavirus disease 2019), as well as dying from substantially with age. Currently, there are insuffi- the disease. In a large study from the US [2], hos- cient data for estimating COVID-19 risks for cancer pitalization for COVID-19 was necessary in 47.46% survivors, i.e., patients in long-term follow-up with- of oncologic patients, who had acquired the disease, out active disease or treatment, but highest risk for and an overall mortality of 14.93% was seen, while severe COVID-19 seems to affect cancer

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 1, 2021

Keywords: oncology; medicine/public health, general

There are no references for this article.